CTI BioPharma Corp. focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis.
Market Cap | 622.201 Million | Shares Outstanding | 108.967 Million | Avg 30-day Volume | 4.54 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.15 |
Price to Revenue | 44.3051 | Debt to Equity | -9.0372 | EBITDA | -111.761 Million |
Price to Book Value | 0.0 | Operating Margin | -770.9177000000001 | Enterprise Value | 599.71 Million |
Current Ratio | 3.604 | EPS Growth | -0.557 | Quick Ratio | 3.492 |
1 Yr BETA | 0.8946 | 52-week High/Low | 7.8 / 1.43 | Profit Margin | -826.012 |
Operating Cash Flow Growth | -78.0928 | Altman Z-Score | -25.0557 | Free Cash Flow to Firm | -33.561 Million |
Please sign in first
none
8.8 Million total shares from 20 transactions
233.7 Thousand total shares from 7 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BIOTECHNOLOGY VALUE FUND II LP |
|
2,665,438 | 2022-08-09 | 2 |
|
0 | 2022-07-07 | 3 | |
CRAIG ADAM R PRESIDENT AND CEO |
|
3,598,691 | 2022-06-30 | 4 |
KIRSKE DAVID EVP, CHIEF FINANCIAL OFFICER |
|
497,397 | 2022-06-17 | 2 |
|
80,000 | 2022-03-09 | 1 | |
|
80,000 | 2022-03-09 | 1 | |
|
80,000 | 2022-03-09 | 1 | |
|
80,000 | 2022-03-09 | 1 | |
|
80,000 | 2022-03-09 | 2 | |
FONG JAMES K SEE REMARKS |
|
3,565 | 2022-02-28 | 1 |
JONES DAVID ANDREW EXECUTIVE VICE PRESIDENT |
|
18,553 | 2021-12-31 | 1 |
SEELEY BRUCE J. EVP, CHIEF OPERATING OFFICER |
|
323,905 | 2021-06-30 | 0 |
|
7,520,600 | 2021-01-07 | 0 | |
|
5,150,400 | 2020-03-02 | 0 | |
|
0 | 2018-09-18 | 0 | |
SINGER JACK W EVP, CHIEF SCIENTIFIC OFFICER |
|
0 | 2018-05-16 | 0 |
BIOTECHNOLOGY VALUE FUND II LP |
|
1,782,594 | 2018-02-08 | 2 |
|
73,718 | 2017-09-28 | 0 | |
|
5,000,000 | 2017-06-13 | 0 | |
|
73,129 | 2017-04-29 | 0 | |
PLUNKETT MATTHEW EVP, CHIEF BUSINESS OFFICER |
|
0 | 2017-03-01 | 0 |
|
0 | 2016-10-02 | 0 | |
|
360,019 | 2016-04-29 | 0 | |
BIANCO LOUIS A EVP, FINANCE & ADMINISTRATION |
|
622,970 | 2016-03-21 | 0 |
|
0 | 2015-09-23 | 0 | |
|
0 | 2015-09-23 | 0 | |
|
No longer subject to file | 2015-04-30 | 0 | |
|
468,937 | 2014-03-28 | 0 | |
|
15,673,981 | 2013-11-25 | 0 | |
BENNER STEVEN E EVP, CHIEF MEDICAL OFFICER |
|
396,705 | 2013-03-21 | 0 |
|
414 | 2012-11-19 | 0 | |
ERAMIAN DANIEL G EVP, CORPORATE COMMUNICATIONS |
|
354,350 | 2012-09-20 | 0 |
STROMATT SCOTT EVP,CLINICAL DEV & REG AFFAIR |
|
No longer subject to file | 2008-04-04 | 0 |
BROWN JADE EVP, CHIEF BUSINESS OFFICER |
|
77,496 | 2006-06-21 | 0 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CTI BIOPHARMA CORP CTIC | 2022-08-12 22:15:03 UTC | 0.9607 | 1.3593 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 21:45:04 UTC | 0.9607 | 1.3593 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 21:15:04 UTC | 0.9607 | 1.3593 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 20:45:04 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 20:15:05 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 19:45:03 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 19:15:05 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 18:45:03 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 18:15:04 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 17:45:04 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 17:15:05 UTC | 0.9602 | 1.3598 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 16:45:04 UTC | 0.9595 | 1.3605 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 16:15:04 UTC | 0.9595 | 1.3605 | 3700000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 15:45:04 UTC | 0.9595 | 1.3605 | 3600000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 15:15:05 UTC | 0.9595 | 1.3605 | 3600000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 14:45:04 UTC | 0.9595 | 1.3605 | 3600000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 14:15:05 UTC | 0.9595 | 1.3605 | 3600000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 13:45:04 UTC | 0.9803 | 1.3397 | 3600000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 13:15:04 UTC | 0.9803 | 1.3397 | 3600000 |
CTI BIOPHARMA CORP CTIC | 2022-08-12 12:45:04 UTC | 0.9803 | 1.3397 | 3600000 |
Get more info on our International short position coverage here
Holder | Issuer | Net Short Position | Position Date | Origin |
---|